Management of bevacizumab toxicity for cancer therapy / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 711-714, 2011.
Artigo
em Chinês
| WPRIM
| ID: wpr-422115
ABSTRACT
Bevacizumab is an efficient and low-toxicity monoclonal antibody towards serum ventricular endothelial growth factor.At present,bevacizumab has been approved by FDA to use clinically for kinds of cancer,such as colorectal cancer,lung cancer,kidney cancer and breast cancer.As more and more patients received bevacizumab cliniclly,it's toxicities are also focused on increasingly.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of International Oncology
Ano de publicação:
2011
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS